Home › NCT07179055
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RecruitingPhase 2
An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.
About the study
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
What is being tested
- VSJ-110 (drug)
- Placebo (drug)
Sponsor: Vanda Pharmaceuticals · Participants: 160 · Started: 2025-10
Contact the study team
- Vanda Pharmaceuticals · Phone: 202-734-3400
Official record on ClinicalTrials.gov — NCT07179055
Locations in the U.S.
| California | Vanda Investigational Site, Newport Beach |
| Massachusetts | Vanda Investigational Site, Andover (Not yet recruiting) |
| North Carolina | Vanda Investigational Site, Shelby (Not yet recruiting) |
| Tennessee | Vanda Investigational Site, Memphis |
| Virginia | Vanda Investigational Site, Lynchburg (Not yet recruiting) |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.